Cemsidomide + Elranatamab for Multiple Myeloma

Overseen By Study Medical Officer

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: C4 Therapeutics, Inc.

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma.

The first part of the study will evaluate different dose levels of cemsidomide in combination with elranatamab in a limited number of subjects. Approximately 3 different dose levels of cemsidomide in combination with elranatamab may be explored. Once a dose level is determined safe, additional subjects may be enrolled through expansion of the dose level. This expansion will provide further exploration of the safety and evaluation of preliminary antimyeloma activity.

Cemsidomide will be taken orally each cycle for 14 days on/14 days off (1 cycle=28 days). Elranatamab will be administered by subcutaneous injection twice a month. Dexamethasone will be administered weekly until a confirmed response but no longer than 4 cycles.

Are You a Good Fit for This Trial?

This trial is for people with multiple myeloma that has come back or hasn't responded to treatment. Participants should be able to take medication orally and receive subcutaneous injections. The full eligibility criteria are not provided, so interested individuals should inquire further.

Inclusion Criteria

Measurable disease based on IMWG criteria

I can take care of myself and am up and about more than half of my waking hours.

I have been diagnosed with multiple myeloma.

Exclusion Criteria

Administration with an investigational product within 30 days preceding the first dose of study intervention

I have not had a stem cell transplant in the last 3 months and do not have active graft vs host disease.

I do not have any active, uncontrolled infections.

What Are the Treatments Tested in This Trial?

Interventions

• Cemsidomide
• Elranatamab

Trial Overview The study tests the safety of a new drug combo: Cemsidomide (oral pill) and Elranatamab (injection), for relapsed/refractory multiple myeloma. It starts by finding a safe dose of Cemsidomide to use with Elranatamab, then expands to more patients at this dose.

How Is the Trial Designed?

Group I: Non-randomized cemsidomide plus elranatamab Experimental Treatment 2 Interventions

Who Is Running the Clinical Trial?

C4 Therapeutics, Inc.

Lead Sponsor

Trials

3

Recruited

480+